drugset / Trial / NCT04632706

Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19

NCT04632706

Phase 1 Completed 24 enrolled MedinCell S.A
RandomizedSequentialDouble-blindOther

Summary

An early stage trial to check how safe and tolerable, as well as how the body handles continuous daily use of Active IMP over 28 days in healthy volunteers.

Timeline

Start
2020-09-22
Primary completion
2021-03-09
Completion
2021-03-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivermectin Small molecule 50 ug/kg Oral
Subject Ivermectin Small molecule 75 ug/kg Oral
Subject Ivermectin Small molecule 100 ug/kg Oral

Indications